Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 10/20 | 0.64 |
| ▸ | PIK3CB | P42338 | 8/20 | 0.64 |
| ▸ | PIM1 | P11309 | 7/20 | 0.64 |
| ▸ | GSK3B | P49841 | 7/20 | 0.64 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.60 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.60 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | HPGDS | O60760 | 4/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | KCNT1 | Q5JUK3 | 3/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2213014 | 0.87 | PIK3CD (0.65) | PIK3CDPIK3CBPIM1GSK3BPIK3CA | |
| SCHEMBL2210330 | 0.86 | PIK3CD (0.63) | PIK3CDPIK3CBPIM1GSK3BPIK3CA | |
| SCHEMBL2215110 | 0.85 | PIK3CD (0.62) | PIK3CDPIK3CBPIM1GSK3BPIK3CA | |
| SCHEMBL2216862 | 0.84 | PIK3CD (0.61) | PIK3CDPIK3CBPIM1GSK3BPIK3CA | |
| SCHEMBL2214569 | 0.83 | PIK3CD (0.59) | PIK3CDPIK3CBPIM1GSK3BPIK3CA | |
| SCHEMBL461218 | 0.83 | PIK3CD (0.68) | PIK3CDPIK3CBPIM1GSK3BPIK3CA | |
| SCHEMBL2214227 | 0.82 | PIK3CD (0.67) | PIK3CDPIK3CBPIM1GSK3BPIK3CA | |
| SCHEMBL2215897 | 0.81 | PIK3CD (0.59) | PIK3CDPIK3CBPIM1GSK3BPIK3CA | |
| SCHEMBL2214801 | 0.81 | PIK3CD (0.55) | PIK3CDPIK3CBPIM1GSK3BPIK3CA | |
| SCHEMBL2213490 | 0.80 | PIK3CD (0.70) | PIK3CDPIK3CBPIM1GSK3BPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8658635-B2 | Benzpyrazol derivatives as inhibitors of PI3 kinases | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-02-25 | — | — | US | claimed |
| EP-2300437-B1 | BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES | GLAXO GROUP LTD (GB) | 2013-11-20 | — | — | EP | claimed |
| US-20110178063-A1 | BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES | GLAXO GROUP LIMITED (GB) | 2011-07-21 | — | — | US | claimed |
| US-9326987-B2 | Indazole derivatives for use in the treatment of influenza virus infection | GLAXO GROUP LIMITED (GB) | 2016-05-03 | — | — | US | disclosed |
| US-8658635-B2 | Benzpyrazol derivatives as inhibitors of PI3 kinases | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-02-25 | — | — | US | disclosed |
| US-8658635-B2 | Benzpyrazol derivatives as inhibitors of PI3 kinases | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-02-25 | — | — | US | disclosed |
| US-8658635-B2 | Benzpyrazol derivatives as inhibitors of PI3 kinases | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-02-25 | — | — | US | disclosed |
| EP-2300437-B1 | BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES | GLAXO GROUP LTD (GB) | 2013-11-20 | — | — | EP | disclosed |
| US-20130165433-A1 | Novel Use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-06-27 | — | — | US | disclosed |
| US-20110178063-A1 | BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES | GLAXO GROUP LIMITED (GB) | 2011-07-21 | — | — | US | disclosed |
| US-20110178063-A1 | BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES | GLAXO GROUP LIMITED (GB) | 2011-07-21 | — | — | US | disclosed |
| US-20110178063-A1 | BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES | GLAXO GROUP LIMITED (GB) | 2011-07-21 | — | — | US | disclosed |
| WO-2009147188-A1 | BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES | GLAXO GROUP LIMITED (GB) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178063-A1 | BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES | PIK3CA, PIK3CD, PI4KA | PIK3CD 2/4885PIK3CB 6/4885PIM1 46/4885 |
| US-20130165433-A1 | Novel Use | HAVCR2, MAVS, ENTPD5 | PIK3CD 2938/4885PIK3CB 1706/4885PIM1 1258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.